This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sova, P. Articles by Kiviat, N. Search for Related Content PubMed PubMed Citation Articles by Sova, P. Articles by Kiviat, N.

Discovery of Novel Methylation Biomarkers in Cervical Carcinoma by Global Demethylation and Microarray Analysis

¹ Department of Pathology, School of Medicine at South Lake Union and ² Division of Medical Genetics, University of Washington, Seattle, Washington

Requests for reprints: Pavel Sova, Department of Pathology, University of Washington, 815 Mercer Street, Box 358050, Seattle, WA 98109-4325. Phone: 206-897-1584; Fax: 206-897-1334. E-mail: ps44{at}u.washington.edu

A genome-wide screening study for identification of hypermethylated genes in invasive cervical cancer (ICC) was carried out to augment our previously discovered panel of three genes found to be useful for detection of ICC and its precursor neoplasia. Putatively hypermethylated and silenced genes were reactivated in four ICC cell lines by treatment with 5-aza-2'-deoxycytidine and trichostatin A and identified on expression microarrays. Thirty-nine of the 235 genes up-regulated in multiple ICC cell lines were further examined to determine the methylation status of associated CpG islands. The diagnostic use of 23 genes that were aberrantly methylated in multiple ICC cell lines were then analyzed in DNA from exfoliated cells obtained from patients with or without ICC. We show, for the first time, that aberrant methylation of six genes (SPARC, TFPI2, RRAD, SFRP1, MT1G, and NMES1) is present in a high proportion of ICC clinical samples but not in normal samples. Of these genes, SPARC and TFPI2 showed the highest frequency of aberrant methylation in ICC specimens (86.4% for either) and together were hypermethylated in all but one ICC cases examined. We conclude that expression profiling of epigenetically reactivated genes followed by methylation analysis in clinical samples is a powerful tool for comprehensive identification of methylation markers. Several novel genes identified in our study may be clinically useful for detection or stratification of ICC and/or of its precursor lesions and provide a basis for better understanding of mechanisms involved in development of ICC. (Cancer Epidemiol Biomarkers Prev 2006;(15)1:114–23)

This article has been cited by other articles:

				S. C. Glockner, M. Dhir, J. M. Yi, K. E. McGarvey, L. Van Neste, J. Louwagie, T. A. Chan, W. Kleeberger, A. P. de Bruine, K. M. Smits, et al. Methylation of TFPI2 in Stool DNA: A Potential Novel Biomarker for the Detection of Colorectal Cancer Cancer Res., June 1, 2009; 69(11): 4691 - 4699. [Abstract] [Full Text] [PDF]

				S. S. Wang, D. J. Smiraglia, Y.-Z. Wu, S. Ghosh, J. S. Rader, K. R. Cho, T. A. Bonfiglio, R. Nayar, C. Plass, and M. E. Sherman Identification of Novel Methylation Markers in Cervical Cancer Using Restriction Landmark Genomic Scanning Cancer Res., April 1, 2008; 68(7): 2489 - 2497. [Abstract] [Full Text] [PDF]

				G. Dawelbait, C. Winter, Y. Zhang, C. Pilarsky, R. Grutzmann, J.-C. Heinrich, and M. Schroeder Structural templates predict novel protein interactions and targets from pancreas tumour gene expression data Bioinformatics, July 1, 2007; 23(13): i115 - i124. [Abstract] [Full Text] [PDF]